204 related articles for article (PubMed ID: 32122369)
1. Parkinson's disease with early motor complications: predicting EQ-5D- 3L utilities from PDQ-39 data in the EARLYSTIM trial.
Zahra M; Durand-Zaleski I; Górecki M; Walleser Autiero S; Barnett G; Schüpbach WMM
Health Qual Life Outcomes; 2020 Mar; 18(1):49. PubMed ID: 32122369
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
3. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
[TBL] [Abstract][Full Text] [Related]
4. Mapping from the Parkinson's Disease Questionnaire PDQ-39 to the Generic EuroQol EQ-5D-3L: The Value of Mixture Models.
Kent S; Gray A; Schlackow I; Jenkinson C; McIntosh E
Med Decis Making; 2015 Oct; 35(7):902-11. PubMed ID: 25926283
[TBL] [Abstract][Full Text] [Related]
5. Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis.
Fundament T; Eldridge PR; Green AL; Whone AL; Taylor RS; Williams AC; Schuepbach WM
PLoS One; 2016; 11(7):e0159340. PubMed ID: 27441637
[TBL] [Abstract][Full Text] [Related]
6. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
Moore A; Young CA; Hughes DA
Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
[TBL] [Abstract][Full Text] [Related]
7. Mapping the COPD Assessment Test onto EQ-5D.
Hoyle CK; Tabberer M; Brooks J
Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
[TBL] [Abstract][Full Text] [Related]
8. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.
Meregaglia M; Borsoi L; Cairns J; Tarricone R
Eur J Health Econ; 2019 Mar; 20(2):181-193. PubMed ID: 28948436
[TBL] [Abstract][Full Text] [Related]
9. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness of the EQ-5D and 8-item Parkinson's Disease Questionnaire (PDQ-8) in a 4-year follow-up study.
Luo N; Ng WY; Lau PN; Au WL; Tan LC
Qual Life Res; 2010 May; 19(4):565-9. PubMed ID: 20204708
[TBL] [Abstract][Full Text] [Related]
11. Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland-Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data.
Madan J; Khan KA; Petrou S; Lamb SE
Pharmacoeconomics; 2017 May; 35(5):549-559. PubMed ID: 28063083
[TBL] [Abstract][Full Text] [Related]
12. Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.
Dafsari HS; Silverdale M; Strack M; Rizos A; Ashkan K; Mahlstedt P; Sachse L; Steffen J; Dembek TA; Visser-Vandewalle V; Evans J; Antonini A; Martinez-Martin P; Ray-Chaudhuri K; Timmermann L;
Mov Disord; 2018 Mar; 33(3):421-430. PubMed ID: 29465787
[TBL] [Abstract][Full Text] [Related]
13. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Patient; 2019 Aug; 12(4):383-392. PubMed ID: 30607809
[TBL] [Abstract][Full Text] [Related]
14. Interpretation of health-related quality of life outcomes in Parkinson's disease from the EARLYSTIM Study.
Martinez-Martin P; Deuschl G; Tonder L; Schnitzler A; Houeto JL; Timmermann L; Rau J; Schade-Brittinger C; Stoker V; Vidailhet M; Krack P;
PLoS One; 2020; 15(8):e0237498. PubMed ID: 32822437
[TBL] [Abstract][Full Text] [Related]
15. Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson's Disease: A Swedish Register-Based Study in 1823 Observations.
Norlin JM; Kellerborg K; Odin P
Pharmacoeconomics; 2021 Oct; 39(10):1141-1149. PubMed ID: 34231134
[TBL] [Abstract][Full Text] [Related]
16. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
[TBL] [Abstract][Full Text] [Related]
17. Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma.
Bharmal M; Hunger M; Schlichting M
Value Health; 2019 Oct; 22(10):1170-1177. PubMed ID: 31563260
[TBL] [Abstract][Full Text] [Related]
18. Real-world assessment of the impact of "OFF" episodes on health-related quality of life among patients with Parkinson's disease in the United States.
Thach A; Jones E; Pappert E; Pike J; Wright J; Gillespie A
BMC Neurol; 2021 Jan; 21(1):46. PubMed ID: 33516182
[TBL] [Abstract][Full Text] [Related]
19. Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson's disease.
Young MK; Ng SK; Mellick G; Scuffham PA
Qual Life Res; 2013 Jun; 22(5):1065-72. PubMed ID: 22782690
[TBL] [Abstract][Full Text] [Related]
20. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
Doble B; Lorgelly P
Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
